Literature DB >> 29698894

Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.

Nathaniel L Baker1, Kevin M Gray2, Brian J Sherman2, Kristen Morella3, Gregory L Sahlem2, Amanda M Wagner2, Aimee L McRae-Clark2.   

Abstract

BACKGROUND: The agreement between self-reported cannabis abstinence with urine cannabinoid concentrations in a clinical trials setting is not well characterized. We assessed the agreement between various cannabinoid cutoffs and self-reported abstinence across three clinical trials, one including contingency management for abstinence.
METHODS: Three cannabis cessation clinical trials where participants reported use and provided weekly urine samples for cannabis and creatinine concentration measurements were included. Bootstrapped data were assessed for agreement between self-reported 7+ day abstinence and urine cannabinoid tests using generalized linear mixed effects models for clustered binary outcomes. One study implemented contingency management for cannabis abstinence. Four hundred and seventy-three participants with 3787 valid urine specimens were included. Urine was analyzed for 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and creatinine using immunoassay methods Biological cutoffs of 50, 100, and 200 ng/ml, as well as changes in CN normalized THCCOOH (25%/50% decrease), were assessed for agreement with self-reported abstinence during the three clinical trials.
RESULTS: Agreement between measured THCCOOH and self-reported abstinence increases with increasing cutoff concentrations, while the agreement with self-reported non-abstinence decreases with increasing cutoff concentrations. Combining THCCOOH cutoffs with recent changes in CN-THCCOOH provides a better agreement in those self-reporting abstinence. Participants in the studies that received CM for abstinence had a lower agreement between self-reported abstinence and returned to use than those in studies that did not have a contingency management component.
CONCLUSION: Using combinations of biological measurements and self-reported abstinence, confirmation of study related abstinence may be verifiable earlier and with greater accuracy than relying on a single measurement.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Clinical trials; Concentrations; Contingency management; Self-Report; Urine cannabinoid

Mesh:

Substances:

Year:  2018        PMID: 29698894      PMCID: PMC5959795          DOI: 10.1016/j.drugalcdep.2018.03.017

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

1.  Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology.

Authors:  William A Vega; Sergio Aguilar-Gaxiola; Laura Andrade; Rob Bijl; Guilherme Borges; Jorge J Caraveo-Anduaga; David J DeWit; Steven G Heeringa; Ronald C Kessler; Bo Kolody; Kathleen R Merikangas; Beth E Molnar; Ellen E Walters; Lynn A Warner; Hans-Ulrich Wittchen
Journal:  Drug Alcohol Depend       Date:  2002-12-01       Impact factor: 4.492

2.  Validity of adolescent self-report of substance use.

Authors:  Robert J Williams; Nadine Nowatzki
Journal:  Subst Use Misuse       Date:  2005       Impact factor: 2.164

3.  Differentiating new marijuana use from residual drug excretion in occasional marijuana users.

Authors:  M A Huestis; E J Cone
Journal:  J Anal Toxicol       Date:  1998-10       Impact factor: 3.367

4.  Assessing the risk of marijuana use disorder among adolescents and adults who use marijuana.

Authors:  Linda Richter; Brandie S Pugh; Samuel A Ball
Journal:  Am J Drug Alcohol Abuse       Date:  2016-06-13       Impact factor: 3.829

5.  A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Authors:  Kevin M Gray; Susan C Sonne; Erin A McClure; Udi E Ghitza; Abigail G Matthews; Aimee L McRae-Clark; Kathleen M Carroll; Jennifer S Potter; Katharina Wiest; Larissa J Mooney; Albert Hasson; Sharon L Walsh; Michelle R Lofwall; Shanna Babalonis; Robert W Lindblad; Steven Sparenborg; Aimee Wahle; Jacqueline S King; Nathaniel L Baker; Rachel L Tomko; Louise F Haynes; Ryan G Vandrey; Frances R Levin
Journal:  Drug Alcohol Depend       Date:  2017-06-10       Impact factor: 4.492

6.  A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Authors:  Frances R Levin; John Mariani; Daniel J Brooks; Martina Pavlicova; Edward V Nunes; Vito Agosti; Adam Bisaga; Maria A Sullivan; Kenneth M Carpenter
Journal:  Addiction       Date:  2013-03-21       Impact factor: 6.526

Review 7.  Review: Pharmacokinetics of illicit drugs in oral fluid.

Authors:  Olaf H Drummer
Journal:  Forensic Sci Int       Date:  2005-04-18       Impact factor: 2.395

8.  A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

Authors:  Aimee L McRae-Clark; Rickey E Carter; Therese K Killeen; Matthew J Carpenter; Amy E Wahlquist; Stacey A Simpson; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2009-08-21       Impact factor: 4.492

Review 9.  Current knowledge on cannabinoids in oral fluid.

Authors:  Dayong Lee; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2013-08-25       Impact factor: 3.345

10.  Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.

Authors:  Deborah S Hasin; Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Bridget F Grant
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

View more
  6 in total

1.  Erratum To: Implementation of a Blind Quality Control Program in Blood Alcohol Analysis.

Authors:  Jackeline Moral; Callan Hundl; Dayong Lee; Maddisen Neuman; Aimee Grimaldi; Maria Cuellar; Peter Stout
Journal:  J Anal Toxicol       Date:  2021-05-14       Impact factor: 3.367

Review 2.  Methods to reduce the incidence of false negative trial results in substance use treatment research.

Authors:  Rachel L Tomko; Erin A McClure; Lindsay M Squeglia; Hayley Treloar Padovano; Aimee L McRae-Clark; Nathaniel L Baker; Matthew J Carpenter; Kevin M Gray
Journal:  Curr Opin Psychol       Date:  2019-01-28

3.  Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial.

Authors:  Aimee L McRae-Clark; Kevin M Gray; Nathaniel L Baker; Brian J Sherman; Lindsay Squeglia; Gregory L Sahlem; Amanda Wagner; Rachel Tomko
Journal:  Drug Alcohol Depend       Date:  2021-09-28       Impact factor: 4.492

4.  Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.

Authors:  Jacob T Borodovsky; Michael J Sofis; Brian J Sherman; Kevin M Gray; Alan J Budney
Journal:  Psychol Addict Behav       Date:  2022-01-27

5.  Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.

Authors:  Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure
Journal:  Curr Addict Rep       Date:  2019-11-19

Review 6.  Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Authors:  Ainhoa Bilbao; Rainer Spanagel
Journal:  BMC Med       Date:  2022-08-19       Impact factor: 11.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.